Statin use in the metabolic syndrome

被引：19

作者：

Lundbye J.B. ^{[1
]}

Thompson P.D. ^{[1
]}

机构：

[1] Department of Cardiology, Hartford Hospital, Hartford, CT 06102-5037

来源：

Current Atherosclerosis Reports | 2005年 / 7卷 / 1期

关键词：

Insulin Resistance; Metabolic Syndrome; Statin; National Cholesterol Education Program; Cholesterol Education Program Adult Treatment;

D O I：

10.1007/s11883-005-0070-9

中图分类号：

学科分类号：

摘要：

The metabolic syndrome is a condition associated with obesity, insulin resistance, hypertension, dyslipidemia, hypercoagulability. and chronic inflammation, all of which increase the risk of cardiovascular disease (CVD). The Third National Cholesterol Education Program Adult Treatment Panel extensively discussed the metabolic syndrome because it is a major health issue in the United States due to the national epidemic of obesity. Statins cause significant CVD risk reduction in patients with the metabolic syndrome by alterations in lipid levels and possibly by decreasing inflammation. Because of the increased CVD risk associated with the metabolic syndrome and extensive clinical trial evidence documenting reduction of CVD risk with statin treatment, all patients with the metabolic syndrome should be evaluated as candidates for statin treatment as part of a multidisciplinary approach to reduce CVD risk. Copyright © 2005 by Current Science Inc.

引用

页码：17 / 21

页数：4

共 51 条

[1]

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA, 285, pp. 2486-2497, (2001)

[2]

Reaven G.M., Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, pp. 1595-1607, (1988)

[3]

Alberti K.G., Zimmet P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabetes Med., 15, pp. 539-553, (1998)

[4]

Comment on the provisional report from the WHO consultation, Diabetic Med., 16, pp. 442-443, (1999)

[5]

Heart Disease and Stroke Statistics - 2004 Update, (2003)

[6]

Moller D.E., Flier J.S., Insulin resistance - Mechanisms, syndromes, and implications, N. Engl. J. Med., 325, pp. 938-948, (1991)

[7]

Kahn C.R., Rosenthal A.S., Immunologic reactions to insulin: Insulin allergy, insulin resistance, and the autoimumme insulin syndrome, Diabetes Care, 2, pp. 283-295, (1979)

[8]

Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L., Prevalence and trends in obesity among US adults, 1999-2000, JAMA, 288, pp. 1723-1727, (2002)

[9]

Kissebah A.H., Vydelingum N., Murray R., Et al., Relation of body fat distribution to metabolic complications of obesity, J. Clin. Endocrinol. Metab., 54, pp. 254-260, (1982)

[10]

Chen K.W., Boyko E.J., Bergstrom R.W., Et al., Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men, Diabetes Care, 18, pp. 747-753, (1995)

← 1 2 3 4 5 6 →